Literature DB >> 27166000

Xeroderma pigmentosum with bilateral ocular surface squamous neoplasia and review of the literature.

Charudutt Kalamkar1, Nishant Radke2, Amrita Mukherjee2, Snehal Radke2.   

Abstract

Xeroderma pigmentosum is a rare genetic disorder associated with various ocular malignancies. Here we report a single paediatric case of xeroderma pigmentosum with bilateral ocular surface squamous neoplasia (OSSN) presenting with diffuse lesion in one eye and a large mass in the other eye. Diffuse OSSN in one eye was treated with topical chemotherapy using mitomycin-C (0.04%) and the large OSSN in the other eye was treated with a combination of surgery and topical chemotherapy. Long-term follow-up and a multimodality treatment approach are necessary to identify and manage recurrences of OSSN in XP. 2016 BMJ Publishing Group Ltd.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27166000      PMCID： PMC4885245          DOI： 10.1136/bcr-2016-215364

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  8 in total

Review 1.  Treatment of ocular surface squamous neoplasia with Mitomycin C.

Authors:  A Gupta; J Muecke
Journal:  Br J Ophthalmol       Date:  2010-05       Impact factor: 4.638

2.  Ocular surface squamous neoplasia in xeroderma pigmentosum: clinical spectrum and outcome.

Authors:  Noopur Gupta; Ritika Sachdev; Radhika Tandon
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-04-12       Impact factor: 3.117

3.  Xeroderma pigmentosum. An inherited diseases with sun sensitivity, multiple cutaneous neoplasms, and abnormal DNA repair.

Authors:  J H Robbins; K H Kraemer; M A Lutzner; B W Festoff; H G Coon
Journal:  Ann Intern Med       Date:  1974-02       Impact factor: 25.391

Review 4.  Oculocutaneous manifestations in xeroderma pigmentosa.

Authors:  J L Goyal; V A Rao; R Srinivasan; K Agrawal
Journal:  Br J Ophthalmol       Date:  1994-04       Impact factor: 4.638

5.  [Ocular malignancies of xeroderma pigmentosum: clinical and therapeutic features].

Authors:  R A Touzri; Z Mohamed; E Khalil; M-B Ilhem; M Insaf; F Bassima; M O Amel
Journal:  Ann Dermatol Venereol       Date:  2008-02-14       Impact factor: 0.777

6.  Management of diffuse ocular surface squamous neoplasia: efficacy and complications of topical chemotherapy.

Authors:  Adam K Rudkin; Lucy Dempster; James S Muecke
Journal:  Clin Exp Ophthalmol       Date:  2014-09-09       Impact factor: 4.207

7.  Combined excision, cryotherapy, and intraoperative mitomycin C (EXCRIM) for localized intraepithelial and squamous cell carcinoma of the conjunctiva.

Authors:  Ahmet M Sarici; Sema Arvas; Halit Pazarli
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-08-16       Impact factor: 3.117

8.  Risk factors for ocular surface squamous neoplasia recurrence after treatment with topical mitomycin C and interferon alpha-2b.

Authors:  Jenna Besley; Juanita Pappalardo; Graham A Lee; Lawrence W Hirst; Stephen J Vincent
Journal:  Am J Ophthalmol       Date:  2013-11-01       Impact factor: 5.258
  8 in total
  4 in total

1.  Bilateral ocular surface squamous neoplasia with bilateral periocular basal cell carcinoma in a case of xeroderma pigmentosum.

Authors:  Rohit Agarwal; Bhavna Chawla; Mohamed Ibrahime Asif; Amar Pujari
Journal:  BMJ Case Rep       Date:  2017-12-02

Review 2.  Xeroderma pigmentosum: an updated review.

Authors:  Alexander Kc Leung; Benjamin Barankin; Joseph M Lam; Kin Fon Leong; Kam Lun Hon
Journal:  Drugs Context       Date:  2022-04-25

3.  Effect of Pegylated Interferon and Mitomycin C on Ocular Surface Squamous Neoplasia in Xeroderma Pigmentosum: A Case Series.

Authors:  Qais S Dirar; Hebah M Musalem; Selwa A F Al-Hazzaa; Abdulaziz A Al Zoba; Amal A Almalki
Journal:  Am J Case Rep       Date:  2020-04-06

4.  Xeroderma Pigmentosum with Simultaneous Cutaneous and Ocular Squamous Cell Carcinoma.

Authors:  Raden Mohamad Rendy Ariezal Effendi; Azmi Fadhlih; Inne Arline Diana; Srie Prihianti Gondokaryono; Reiva Farah Dwiyana
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-02-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.